- Avivagen (VIV) has announced its unaudited financial results for the third quarter ended July 31, 2022
- Net revenues of $48,606 and a comprehensive loss of $(1,901,453) for the three-month period ended July 31, 2022
- The company appointed Ira Levy as interim CFO, effective immediately
- Avivagen is a life sciences corporation which develops science-based, natural health products for animals
- Avivagen Inc. (VIV) remains unchanged, trading at C$0.17 per share at 3:20 pm ET
Avivagen (VIV) has announced its unaudited financial results for the third quarter ended July 31, 2022.
Highlights:
- Net revenues of $48,606 and a comprehensive loss of $(1,901,453) for the three-month period ended July 31, 2022. This compares to revenues of $878,811 and a comprehensive loss of $(1,209,130) for the same period last year
- Net revenues of $408,201 and a comprehensive loss of $(4,757,982) for the nine-month period ended July 31, 2022. This compares to revenues of $1,300,412 and a comprehensive loss of $(4,673,079) for the same period last year
- As at July 31, 2022, the company reported total assets of $1,660,004 (current assets of $1,545,391), total liabilities of $6,920,903, and shareholders’ deficit of $(5,260,899)
The company also appointed Ira Levy as interim CFO, effective immediately.
Levy has over 15 years of experience in a wide range of high-growth, early-stage companies, both public and private. He has an MBA from the Schulich School of Business in addition to his professional designation as a Chartered Accountant.
Avivagen is a life sciences corporation which develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s health defenses.
The company’s products are based on OxC-beta Technology. Through the support of the animal’s immune function, the technology provides a non-antibiotic means of promoting health and growth. Avivagen’s OxC-beta Livestock product is safe, and effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.
Avivagen Inc. (VIV) remains unchanged, trading at C$0.17 per share at 3:20 pm ET.
